...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug delivery and translational research >Concurrent oral and inhalation drug delivery using a dual formulation system: The use of oral theophylline carrier with combined inhalable budesonide and terbutaline
【24h】

Concurrent oral and inhalation drug delivery using a dual formulation system: The use of oral theophylline carrier with combined inhalable budesonide and terbutaline

机译：使用双重制剂系统同时口服和吸入药物：口服茶碱载体与可吸入布地奈德和特布他林的组合使用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A novel approach to concurrently deliver oral and inhaled drugs as a single formulation is presented. A triple therapy containing theophylline (THEO; orally delivered) with budesonide (BUD) and terbutaline (TERB; as single and co-spray-dried inhaled powders) was prepared as an ordered mix, with THEO acting as a carrier. The aerosolisation performance of THEO formulations containing BUD and TERB alone, physical mix and co-spray-dried powder was evaluated using a next-generation impactor (NGI). Physicochemical properties were investigated using electron microscopy, laser diffraction, dynamic vapour sorption and thermal analysis. NGI analysis indicated that >99 % of the THEO powder was >4.46 μm, with >90 % dissolved within 5 min. Particle size analysis showed TEB and BUD samples were of a suitable size for inhalation. Thermal and moisture analysis suggested powders to be stable at room temperature up to 70 % RH. Aerosol studies indicated a different performance of BUD and TERB depending on the mixing procedure. The co-spray-dried formulation showed the highest performance, with a fine particle fraction (≤4.46 μm) of BUD and TERB of 34.39 ± 3.56 and 33.61 ± 5.67 %, respectively. Such observations suggest that this multicomponent drug delivery system could be developed to concomitantly deliver oral and inhaled drugs, an approach that, to date, does not exist. Ultimately, this technology potentially reduces the requirement for multiple therapies and increases patient compliance.
机译：提出了一种同时递送口服和吸入药物作为单一制剂的新颖方法。制备了包含茶碱（THEO;口服）与布地奈德（BUD）和特布他林（TERB;作为单次和共同喷雾干燥的吸入粉剂）的三联疗法，以有序的混合物形式，以THEO为载体。使用下一代冲击器（NGI）评估仅包含BUD和TERB，物理混合物和共喷雾干燥粉末的THEO制剂的雾化性能。使用电子显微镜，激光衍射，动态蒸气吸附和热分析研究了理化性质。 NGI分析表明，> 99％的THEO粉末> 4.46μm，> 90％在5分钟内溶解。粒度分析表明，TEB和BUD样品的大小适合吸入。热和湿气分析表明粉末在室温下最高相对湿度为70％时是稳定的。气溶胶研究表明，BUD和TERB的性能取决于混合程序。共喷雾干燥的制剂表现出最高的性能，BUD和TERB的细颗粒分数（≤4.46μm）分别为34.39±3.56和33.61±5.67％。这些观察结果表明，可以开发这种多组分药物输送系统，以同时输送口服和吸入药物，迄今为止尚不存在这种方法。最终，该技术潜在地减少了对多种疗法的需求并提高了患者的依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号